These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21918173)

  • 1. Common cancer stem cell gene variants predict colon cancer recurrence.
    Gerger A; Zhang W; Yang D; Bohanes P; Ning Y; Winder T; LaBonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; El-Khoueiry A; Kahn M; Lenz HJ
    Clin Cancer Res; 2011 Nov; 17(21):6934-43. PubMed ID: 21918173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.
    Bohanes P; Yang D; Loupakis F; LaBonte MJ; Gerger A; Ning Y; Lenz C; Lenz F; Wakatsuki T; Zhang W; Benhaim L; El-Khoueiry A; El-Khoueiry R; Lenz HJ
    Pharmacogenomics J; 2015 Jun; 15(3):226-34. PubMed ID: 25487679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.
    Stotz M; Herzog SA; Pichler M; Smolle M; Riedl J; Rossmann C; Bezan A; Stöger H; Renner W; Berghold A; Gerger A
    Anticancer Res; 2017 Apr; 37(4):2011-2018. PubMed ID: 28373475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer.
    Lurje G; Hendifar AE; Schultheis AM; Pohl A; Husain H; Yang D; Manegold PC; Ning Y; Zhang W; Lenz HJ
    Pharmacogenet Genomics; 2009 Feb; 19(2):95-102. PubMed ID: 18987561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
    Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
    J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence.
    Páez D; Gerger A; Zhang W; Yang D; Labonte MJ; Benhanim L; Kahn M; Lenz F; Lenz C; Ning Y; Wakatsuki T; Loupakis F; Lenz HJ
    Pharmacogenomics J; 2014 Apr; 14(2):142-50. PubMed ID: 23817222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy.
    Szkandera J; Herzog S; Pichler M; Stiegelbauer V; Stotz M; Schaberl-Moser R; Samonigg H; Asslaber M; Lax S; Leitner G; Renner W; Lenz HJ; Berghold A; Gerger A
    Pharmacogenomics J; 2015 Oct; 15(5):391-6. PubMed ID: 25665511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
    Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
    Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
    Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
    O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
    J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer.
    Lurje G; Zhang W; Yang D; Groshen S; Hendifar AE; Husain H; Nagashima F; Chang HM; Fazzone W; Ladner RD; Pohl A; Ning Y; Iqbal S; El-Khoueiry A; Lenz HJ
    Pharmacogenet Genomics; 2008 Feb; 18(2):161-8. PubMed ID: 18192902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients.
    Szkandera J; Pichler M; Absenger G; Stotz M; Weissmueller M; Samonigg H; Asslaber M; Lax S; Leitner G; Winder T; Renner W; Gerger A
    Clin Cancer Res; 2014 Mar; 20(6):1687-97. PubMed ID: 24470513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer.
    Zhang W; Press OA; Haiman CA; Yang DY; Gordon MA; Fazzone W; El-Khoueiry A; Iqbal S; Sherrod AE; Lurje G; Lenz HJ
    J Clin Oncol; 2007 Aug; 25(24):3726-31. PubMed ID: 17704422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
    Lurje G; Zhang W; Schultheis AM; Yang D; Groshen S; Hendifar AE; Husain H; Gordon MA; Nagashima F; Chang HM; Lenz HJ
    Ann Oncol; 2008 Oct; 19(10):1734-41. PubMed ID: 18550579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
    Schippinger W; Samonigg H; Schaberl-Moser R; Greil R; Thödtmann R; Tschmelitsch J; Jagoditsch M; Steger GG; Jakesz R; Herbst F; Hofbauer F; Rabl H; Wohlmuth P; Gnant M; Thaler J;
    Br J Cancer; 2007 Oct; 97(8):1021-7. PubMed ID: 17895886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of patients with high-risk stage II colon cancer for adjuvant therapy.
    Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Landmann RG; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
    Dis Colon Rectum; 2008 May; 51(5):503-7. PubMed ID: 18322753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
    Haller DG; Catalano PJ; Macdonald JS; O'Rourke MA; Frontiera MS; Jackson DV; Mayer RJ
    J Clin Oncol; 2005 Dec; 23(34):8671-8. PubMed ID: 16314627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
    Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D
    J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.